Five‐year follow‐up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma‐derived vaccine in children: Immunogenicity and anamnestic responses
Ching‐Lung Lai, Benjamin Chun‐Yu Wong, Eng‐Kiong Yeoh, Wai‐Ling Lim, Wai‐Kwan Chang, Hsiang‐Ju Lin – 1 October 1993 – In a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5‐μg doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 mo (group 1), three 5‐μg doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 mo (group 2) or three 10‐μg doses of plasma‐derived hepatitis B vaccine (group 3).